Rational development of new anticancer drugs involves the identification of potential targets in tumor cells and the development of reagents selectively acting at such targets. It is now possible to design target- specific """"""""genetic drugs"""""""", such as antisense oligonucleotides, peptides, or vectors for gene therapy, directly on the basis of the structure of the selected target gene. Some prototype genetic drugs targeting specific oncogenes were reported to have a selective cytostatic or cytotoxic effect on neoplastically transformed relative to untransformed cells. Tumor- specific changes in the structure or expression of known oncogenes, however, do not provide all the determinants of tumor specificity for either conventional or genetic anticancer drugs. The present application proposes to undertake a general search for genetic drugs that would induce selective cytotoxicity or growth arrest in tumor cells, and to identify the cellular targets of such drugs. This search will be based on the new methodology for expression selection of genetic suppressor elements (GSEs), short cDNA fragments that encode peptides or antisense RNA sequences interfering with the function of genes from which they are derived. This methodology was developed in a bacterial model and then used in mammalian cells to isolate a series of GSEs inhibiting human topoisomerase II. In subsequent studies, GSE selection was conducted using a retroviral expression library carrying normalized (uniform abundance) fragments of total cellular cDNA from NIH 3T3 cells. These studies resulted in the isolation of several GSEs derived from previously unknown genes associated with drug resistance or neoplastic transformation. The principle of expression selection of GSEs from retroviral libraries of normalized cellular cDNA will now be combined with the use of a tightly regulated inducible promoter and negative selection techniques, to isolate GSEs of unknown nature, which are cytostatic or cytotoxic to cells in which they are expressed. GSEs that show selective inhibition of transformed relative to untransformed mouse fibroblasts, or that are cytotoxic to human HeLa carcinoma cells, will be isolated and sequenced. The activity of the isolated GSEs will be tested on cell lines derived from different types of mouse or human tumors, and on normal cells. Full- length human cDNA sequences of the genes targeted by the selected GSEs will be cloned and their expression patterns will be characterized. The cloned genes will be used individually to isolate the most efficient GSEs interfering with their functions. These GSEs will then be tested for in vitro anti tumor activity, in the form of retroviral vectors or chemically synthesized peptides or oligonucleotides. It is hoped that the proposed studies will lead to the identification of new targets and prototype genetic drugs with potential utility for the treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA062099-01
Application #
2103103
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1994-01-19
Project End
1996-11-30
Budget Start
1994-01-19
Budget End
1994-11-30
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Illinois at Chicago
Department
Genetics
Type
Schools of Medicine
DUNS #
121911077
City
Chicago
State
IL
Country
United States
Zip Code
60612
Shtutman, Michael; Maliyekkel, Anil; Shao, Yu et al. (2010) Function-based gene identification using enzymatically generated normalized shRNA library and massive parallel sequencing. Proc Natl Acad Sci U S A 107:7377-82
Chan, Chi Yu; Carmack, C Steven; Long, Dang D et al. (2009) A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinformatics 10 Suppl 1:S33
Yates, Kristin E; Korbel, Gregory A; Shtutman, Michael et al. (2008) Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell 7:609-21
Broude, Eugenia V; Demidenko, Zoya N; Vivo, Claire et al. (2007) p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle 6:1468-71
Broude, E V; Swift, M E; Vivo, C et al. (2007) p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 26:6954-8
Shao, Yu; Chan, Chi Yu; Maliyekkel, Anil et al. (2007) Effect of target secondary structure on RNAi efficiency. RNA 13:1631-40
Barre, Benjamin; Vigneron, Arnaud; Perkins, Neil et al. (2007) The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13:4-11
Chen, Yuhong; Dokmanovic, Milos; Stein, Wilfred D et al. (2006) Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cells. Cancer Res 66:8749-61
Davidovich, Irina A; Levenson, Anait S; Levenson Chernokhvostov, Victor V (2004) Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance. Cancer Lett 211:189-97
Shay, Jerry W; Roninson, Igor B (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23:2919-33

Showing the most recent 10 out of 34 publications